Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) shares gapped up prior to trading on Monday. The stock had previously closed at $7.2795, but opened at $7.5320. Coloplast A/S shares last traded at $7.5320, with a volume of 1,802 shares traded.
Analyst Upgrades and Downgrades
Separately, Barclays upgraded Coloplast A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.
Check Out Our Latest Stock Analysis on CLPBY
Coloplast A/S Price Performance
The company’s 50 day moving average price is $6.87 and its 200-day moving average price is $6.76. The company has a market cap of $16.94 billion, a price-to-earnings ratio of 35.79, a PEG ratio of 3.64 and a beta of 0.10. The company has a debt-to-equity ratio of 1.51, a quick ratio of 0.94 and a current ratio of 1.56.
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $0.09 EPS for the quarter, meeting the consensus estimate of $0.09. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. Coloplast A/S had a net margin of 10.57% and a return on equity of 42.25%. On average, equities research analysts forecast that Coloplast A/S Sponsored ADR will post 0.37 earnings per share for the current fiscal year.
Coloplast A/S Company Profile
Coloplast A/S is a Danish medical device company that develops and markets products and services for people with intimate health care needs. Its main business areas include ostomy care, continence care, wound and skin care, and urology care. Its products include ostomy bags and accessories, catheters and other continence products, wound dressings, and devices used in urological procedures. Coloplast also provides voice and respiratory care products, including solutions for people who have had a laryngectomy.
Featured Articles
- Five stocks we like better than Coloplast A/S
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
